HF
KZR

HRT Financial’s Kezar Life Sciences KZR Stock Holding History

HRT Financial’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,096
Closed -$8K – 2866
2024
Q3 		$8K Sell
1,096
-6,678
-86% -$40.3K ﹤0.01% 2240
2024
Q2 		$46K Buy
+7,774
New +$59.1K ﹤0.01% 1842
2024
Q1 		– Sell
-10,379
Closed -$98K – 2724
2023
Q4 		$98K Buy
+10,379
New +$91.2K ﹤0.01% 1892
2023
Q2 		– Sell
-2,595
Closed -$81K – 2891
2023
Q1 		$81K Buy
+2,595
New +$150K ﹤0.01% 2088
2022
Q3 		– Sell
-3,245
Closed -$268K – 3188
2022
Q2 		$268K Buy
3,245
+962
+42% +$84.9K ﹤0.01% 2089
2022
Q1 		$379K Buy
+2,283
New +$328K ﹤0.01% 2068

Other funds holding KZR

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

HRT Financial's KZR Position: Q4 2024 in Review

HRT Financial sold out of Kezar Life Sciences (KZR) in Q4 2024, closing a stake of 1,096 shares — an estimated $8K sold.

HRT Financial first reported a position in KZR in Q1 2022 and held it in 6 quarters. The position peaked at $379K in Q1 2022. 43 funds tracked by Wall St. Rank hold KZR as of Q4 2024.

  • HRT Financial reported no remaining Kezar Life Sciences position as of Q4 2024 after selling out during the quarter.
  • HRT Financial sold 1,096 Kezar Life Sciences shares in Q4 2024, an estimated $8K.
  • HRT Financial first reported a position in Kezar Life Sciences in Q1 2022 and held it in 6 quarters.
  • HRT Financial's Kezar Life Sciences position peaked at $379K in Q1 2022.
  • 43 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q4 2024.

Based on HRT Financial's 13F filing for Q4 2024, filed 14 Feb 2025.